{"success":true,"data":{"pressRelease":{"id":"160720","rtpr_id":"nGNX5YDnGZ-20261005","ticker":"DRTS","exchange":"NASDAQ","all_tickers":["DRTS","DRTSW"],"title":"Alpha Tau to Participate in October Investor Conferences","author":"Globe Newswire","published_at":"2026-10-05T13:45:04.110Z","article_body":"JERUSALEM, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (\"Alpha\nTau\", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the\ninnovative alpha-radiation cancer therapy Alpha DaRT(®), today announced that\ncompany management will participate in the following investor conferences in\nOctober 2026.\n\n Event:     Fall Focus: Barclays Biotech 1x1 Day  \n Format:    1x1 Meetings                          \n Date:      Tuesday, October 6, 2026              \n Location:  New York, NY                          \n\n  \n\n Event:     Investment Generation Conference  \n Format:    Presentation                      \n Date:      Thursday, October 15, 2026        \n Time:      12:30 – 1:00 PM                   \n Location:  Rishon Letzion, Israel            \n\n\n\nAbout Alpha Tau Medical Ltd.\n\nFounded in 2016, Alpha Tau is an Israeli oncology therapeutics company that\nfocuses on research, development, and potential commercialization of the Alpha\nDaRT for the treatment of solid tumors. The technology was initially developed\nby Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.\n\nAbout Alpha DaRT(®)\n\nAlpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable\nhighly potent and conformal alpha-irradiation of solid tumors by intratumoral\ndelivery of radium-224 impregnated sources. When the radium decays, its\nshort-lived daughters are released from the sources and disperse while\nemitting high-energy alpha particles with the goal of destroying the tumor.\nSince the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims\nto mainly affect the tumor, and to spare the healthy tissue around it.\n\nInvestor Relations Contact:\n\nIR@alphatau.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/a9de6f03-a487-4934-98e9-d25cdb4c8bed)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX5YDnGZ-20261005","title":"Alpha Tau to Participate in October Investor Conferences","author":"Globe Newswire","ticker":"DRTS","created":"2026-10-05T13:45:04.110Z","tickers":["DRTS","DRTSW"],"exchange":"NASDAQ","article_body":"JERUSALEM, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (\"Alpha\nTau\", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the\ninnovative alpha-radiation cancer therapy Alpha DaRT(®), today announced that\ncompany management will participate in the following investor conferences in\nOctober 2026.\n\n Event:     Fall Focus: Barclays Biotech 1x1 Day  \n Format:    1x1 Meetings                          \n Date:      Tuesday, October 6, 2026              \n Location:  New York, NY                          \n\n  \n\n Event:     Investment Generation Conference  \n Format:    Presentation                      \n Date:      Thursday, October 15, 2026        \n Time:      12:30 – 1:00 PM                   \n Location:  Rishon Letzion, Israel            \n\n\n\nAbout Alpha Tau Medical Ltd.\n\nFounded in 2016, Alpha Tau is an Israeli oncology therapeutics company that\nfocuses on research, development, and potential commercialization of the Alpha\nDaRT for the treatment of solid tumors. The technology was initially developed\nby Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.\n\nAbout Alpha DaRT(®)\n\nAlpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable\nhighly potent and conformal alpha-irradiation of solid tumors by intratumoral\ndelivery of radium-224 impregnated sources. When the radium decays, its\nshort-lived daughters are released from the sources and disperse while\nemitting high-energy alpha particles with the goal of destroying the tumor.\nSince the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims\nto mainly affect the tumor, and to spare the healthy tissue around it.\n\nInvestor Relations Contact:\n\nIR@alphatau.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/a9de6f03-a487-4934-98e9-d25cdb4c8bed)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-05T13:45:04.149074414Z","server_sent_at_ms":1791207904149},"received_at":"2026-10-05T13:45:04.199Z","source_url":null},"analysis":{"id":"149275","press_release_id":"160720","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Alpha Tau Medical will participate in two October investor conferences: 1x1 meetings at the Barclays Biotech 1x1 Day in New York on October 6 and a presentation at the Investment Generation Conference in Rishon Letzion, Israel on October 15.\n\nThe release contains no new clinical, regulatory, or financial information and is largely a scheduling notice.\n\nAttendance at these conferences may offer management a platform to discuss its Alpha DaRT alpha-radiation cancer therapy, but it is routine in nature.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine investor conference participation notice with no new disclosures."},"keyFigures":{},"namedEntities":{"people":[{"name":"Itzhak Kelson","role":"co-developer of Alpha DaRT, Tel Aviv University"},{"name":"Yona Keisari","role":"co-developer of Alpha DaRT, Tel Aviv University"}],"products":["Alpha DaRT"],"companies":[{"name":"Alpha Tau Medical Ltd.","ticker":"DRTS","relationship":"filer"},{"name":"Barclays","relationship":"conference host"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement of investor conference participation with no new financial, clinical, or regulatory information."},"tickerRelevance":{"others":[{"ticker":"DRTSW","relevance":"subsidiary warrant listing of the filer"}],"primary":"DRTS"},"globalImportance":5,"audienceRelevance":5,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine-conference-notice","issuerAuthored":true}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Alpha Tau Medical will participate in two October investor conferences: 1x1 meetings at the Barclays Biotech 1x1 Day in New York on October 6 and a presentation at the Investment Generation Conference in Rishon Letzion, Israel on October 15.\n\nThe release contains no new clinical, regulatory, or financial information and is largely a scheduling notice.\n\nAttendance at these conferences may offer management a platform to discuss its Alpha DaRT alpha-radiation cancer therapy, but it is routine in nature.","key_figures":{},"named_entities":{"people":[{"name":"Itzhak Kelson","role":"co-developer of Alpha DaRT, Tel Aviv University"},{"name":"Yona Keisari","role":"co-developer of Alpha DaRT, Tel Aviv University"}],"products":["Alpha DaRT"],"companies":[{"name":"Alpha Tau Medical Ltd.","ticker":"DRTS","relationship":"filer"},{"name":"Barclays","relationship":"conference host"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-05T13:45:08.049Z","global_importance":5,"audience_relevance":5,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine-conference-notice","issuerAuthored":true}},"durationMs":3828,"modelName":"glm-5.3-flashx"}}